210 related articles for article (PubMed ID: 34659897)
1. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela A; Vasco-Mogorrón MA; Campillo JA; Cabañas V; Remigia MJ; Berenguer M; García-Garay MC; Blanquer M; Cava C; Galian JA; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; de la Rubia J; Teruel AI; Muro M; Periago A
Am J Cancer Res; 2021; 11(9):4438-4454. PubMed ID: 34659897
[TBL] [Abstract][Full Text] [Related]
2. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
3. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
5. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
6. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
7. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
8. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
[TBL] [Abstract][Full Text] [Related]
9. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.
Yu W; Li J; Chen L
Int J Clin Exp Med; 2014; 7(11):4051-62. PubMed ID: 25550914
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X; Jia S; Chu Y; Tian B; Gao Y; Zhang C; Zheng Y; Jia W; Liu X; Yuan R; Zhang N; Feng J; Dong H; Xin X; Chang Z; Cao Z; Tang H; Gao G
Front Oncol; 2022; 12():938550. PubMed ID: 36185185
[TBL] [Abstract][Full Text] [Related]
13. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
Front Oncol; 2022; 12():938392. PubMed ID: 36276097
[TBL] [Abstract][Full Text] [Related]
14. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
[TBL] [Abstract][Full Text] [Related]
15. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
Tang HKK; Fung CY; Morgan GJ; Kumar S; Siu L; Ip HWA; Yip SF; Lau KNH; Lau CK; Lee H; Leung KH; Kho B; Wong H; Ngai C; Hwang YY; Sim J; Kwong YL; Chim CS
Ther Adv Hematol; 2022; 13():20406207221082043. PubMed ID: 35465644
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
17. What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
Gao W; Du J; Liu J; Zhou H; Zhang Z; Jian Y; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Front Oncol; 2020; 10():538126. PubMed ID: 33194599
[TBL] [Abstract][Full Text] [Related]
18. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
Du C; Mao X; Xu Y; Yan Y; Yuan C; Du X; Liu J; Fan H; Wang Q; Sui W; Deng S; Fu M; Li Z; Li C; Zhao J; Yi S; Liu L; Hao M; Zou D; Zhao Y; Qiu L; An G
Leuk Lymphoma; 2020 May; 61(5):1201-1210. PubMed ID: 31842644
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
20. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
